M&A Deal Summary |
|
|---|---|
| Date | 2004-08-24 |
| Target | Celltech Group |
| Sector | Healthcare Services |
| Buyer(s) | UCB |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.5B GBP |
| Advisor(s) | Morgan Stanley J.P. Morgan Securities (Financial) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1928 |
| Sector | Life Science |
| Employees | 9,000 |
| Revenue | 6.2B EUR (2024) |
UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 11 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 3 of 9 |
| Country: United Kingdom M&A | 1 of 2 |
| Year: 2004 M&A | 1 of 1 |
| Size (of disclosed) | 2 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-01-01 |
Solutia - Resins Additives and Adhesives Division
St Louis, Missouri, United States Solutia, Inc. liquid and powder-coatings resins, additives, and adhesives products used primarily in industrial coatings, with an emphasis on the metal and automotive segments. |
Buy | $500M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-01-08 |
UCB - Over-The-Counter Business
France UCB - Over-The-Counter Business comprises mature products with strong brand names (a.o. Carbolevure, Revitalose, Balsoclase, Toclase), UCB - Over-The-Counter Business assets in France, Benelux, Switzerland and Greece. |
Sell | - |
